Alexey S. Kalpinskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexey S. Kalpinskiy has a total of 351 co-authors. Here are the top co-authors by number of shared publications:
- Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
22 shared publications - Boris Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia
20 shared publications - Kirill M. Nyushko
National Medical Research Radiological Center, Ministry of Health of Russia
12 shared publications K. M. Nyushko
P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
9 shared publications- N. V. Vorobyev
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center
9 shared publications - Ovsep A. Mailyan
National Medical Research Radiological Center, Ministry of Health of Russia
9 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in The EANM Journal
- Vol. 5
Imaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- 23 October 2026
- Published by Elsevier in The EANM Journal
- Vol. 5
Open AccessImaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- Open Access
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Open AccessAnalysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- Open Access
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 275-283
Real-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study
Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 275-283
Open AccessReal-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study
Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 41-46
Global coagulation tests in pharmacological prophylaxis of venous thromboembolism in patients with prostate cancer after radical prostatectomy
A significant problem in oncology is venous thromboembolic (VTE) complications. Thrombosis detected in a patient with a malignant neoplasm of the prostate gland increases the risk of death by 3.4 times compared to patients without it. The prevalence of tumors in this localization, the use of an integrated approach to treatment, including before surgery, the risk of hemorrhagic complications, age and concomitant diseases of patients make the problem of the effectiveness and safety of thrombosis prevention relevant. Objective. Determine the most appropriate coagulation test to monitor the effectiveness and safety of pharmacological prevention of VTE in patients with malignant neoplasm of the prostate gland after radical prostatectomy. Material and methods. The study included 44 patients diagnosed with prostate cancer. All patients underwent radical prostatectomy. Pharmacological prevention of VTE was performed with low-molecular-weight heparin (LWH) — calcium nadroparin in a standard dose, according to the recommendations of the American Society of Clinical Oncology (ASCO). Blood was collected for laboratory tests at 3 control points: the day of hospitalization, after surgery before the first administration of LWH, at the peak of the LWH effect 3—3.5 hours after subcutaneous administration. Results. The K interval of the thromboelastogram changed more frequently at all control points of the study. The maximum amplitude allowed us to identify a tendency to hypercoagulation before the start of pharmacological prophylaxis. The clot growth rate of the thrombodynamics test showed the most pronounced changes depending on the stage of treatment. The advantage of the thrombodynamics test is the known range of LMWH effectiveness, which makes this method more optimal and convenient to use. Conclusion. Global coagulation tests during pharmacological prophylaxis of thrombosis in the postoperative period were more sensitive to changes in the state of hemostasis compared to activated partial thromboplastin time.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 41-46
Global coagulation tests in pharmacological prophylaxis of venous thromboembolism in patients with prostate cancer after radical prostatectomy
A significant problem in oncology is venous thromboembolic (VTE) complications. Thrombosis detected in a patient with a malignant neoplasm of the prostate gland increases the risk of death by 3.4 times compared to patients without it. The prevalence of tumors in this localization, the use of an integrated approach to treatment, including before surgery, the risk of hemorrhagic complications, age and concomitant diseases of patients make the problem of the effectiveness and safety of thrombosis prevention relevant. Objective. Determine the most appropriate coagulation test to monitor the effectiveness and safety of pharmacological prevention of VTE in patients with malignant neoplasm of the prostate gland after radical prostatectomy. Material and methods. The study included 44 patients diagnosed with prostate cancer. All patients underwent radical prostatectomy. Pharmacological prevention of VTE was performed with low-molecular-weight heparin (LWH) — calcium nadroparin in a standard dose, according to the recommendations of the American Society of Clinical Oncology (ASCO). Blood was collected for laboratory tests at 3 control points: the day of hospitalization, after surgery before the first administration of LWH, at the peak of the LWH effect 3—3.5 hours after subcutaneous administration. Results. The K interval of the thromboelastogram changed more frequently at all control points of the study. The maximum amplitude allowed us to identify a tendency to hypercoagulation before the start of pharmacological prophylaxis. The clot growth rate of the thrombodynamics test showed the most pronounced changes depending on the stage of treatment. The advantage of the thrombodynamics test is the known range of LMWH effectiveness, which makes this method more optimal and convenient to use. Conclusion. Global coagulation tests during pharmacological prophylaxis of thrombosis in the postoperative period were more sensitive to changes in the state of hemostasis compared to activated partial thromboplastin time.
- Open Access
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Open AccessEfficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- 27 June 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (3)
Surgical management of patients with local recurrence of renal cancer. Prognostic factors of survival
Treatment of local recurrence of renal cell carcinoma (RCC) is a serious surgical and therapeutic problem. Currently, there is no single standardized treatment strategy for patients in this group. Objective. Determination of prognostic factors for overall and tumor-specific survival (OS and NSV, respectively) of patients after surgical treatment for RCC local recurrence to assess its efficacy. Material and methods. From May 2007 to April 2024, 53 patients with local recurrence of RCC were operated on in the oncourology department of the P.A. Herzen Moscow Oncology Research Institute. Of them, 18 (34%) were operated on for primary kidney tumor (12 cases underwent nephrectomy, 6 –kidney resection) at the P.A. Herzen Moscow Scientific Research Institute, 35 (66%) — at their place of residence (16 underwent nephrectomy, 14 — kidney resection, 5 — radiofrequency thermoablation). During single- and multivariate analyses of a number of pre- and intraoperative parameters, as well as the results of pathomorphological examination, the main prognostic factors of overall (OS) and cancer-specific survival (CSS) of patients were determined. Results. In multivariate analysis, the most significant factors for OS were the number of tumor nodes (HR=3.201, p=0.003), microvascular invasion (HR=103.330, p=0.002), and for CSS — the number of recurrent tumor nodes (HR=3.201, p=0.003) and high tumor malignancy (G3—4) (HR=6.304, p=0.025). Conclusion. The distant oncologic outcomes of surgical treatment of patients with local recurrence of RCC are influenced by a number of factors: microvascular invasion of the tumor, the number of recurrent tumor nodes, and the high degree of tumor malignancy.
- 27 June 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (3)
Surgical management of patients with local recurrence of renal cancer. Prognostic factors of survival
Treatment of local recurrence of renal cell carcinoma (RCC) is a serious surgical and therapeutic problem. Currently, there is no single standardized treatment strategy for patients in this group. Objective. Determination of prognostic factors for overall and tumor-specific survival (OS and NSV, respectively) of patients after surgical treatment for RCC local recurrence to assess its efficacy. Material and methods. From May 2007 to April 2024, 53 patients with local recurrence of RCC were operated on in the oncourology department of the P.A. Herzen Moscow Oncology Research Institute. Of them, 18 (34%) were operated on for primary kidney tumor (12 cases underwent nephrectomy, 6 –kidney resection) at the P.A. Herzen Moscow Scientific Research Institute, 35 (66%) — at their place of residence (16 underwent nephrectomy, 14 — kidney resection, 5 — radiofrequency thermoablation). During single- and multivariate analyses of a number of pre- and intraoperative parameters, as well as the results of pathomorphological examination, the main prognostic factors of overall (OS) and cancer-specific survival (CSS) of patients were determined. Results. In multivariate analysis, the most significant factors for OS were the number of tumor nodes (HR=3.201, p=0.003), microvascular invasion (HR=103.330, p=0.002), and for CSS — the number of recurrent tumor nodes (HR=3.201, p=0.003) and high tumor malignancy (G3—4) (HR=6.304, p=0.025). Conclusion. The distant oncologic outcomes of surgical treatment of patients with local recurrence of RCC are influenced by a number of factors: microvascular invasion of the tumor, the number of recurrent tumor nodes, and the high degree of tumor malignancy.
- 19 March 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (1)
Surgical treatment of local renal cell carcinoma recurrence. Surgical aspects and oncological results
Introduction. Treatment of local RCC recurrence is a serious surgical and therapeutic problem. There is no single standard strategy for the treatment of locally recurrent RCC. Objective: to evaluate the short- and long-term results of surgical treatment of patients with local RCC recurrence. Material and methods. Among all participants (n=53), 48 patients had isolated local RCC recurrence (group 1), and 5 had synchronous metastases (group 2). All patients had one or more local foci of RCC and underwent radical removal of all foci from may 2007 to January 2024. In distant metastases, metastasectomy was performed. Results. Laparotomy was the preferred access (75.4 %). The average duration of surgery was 167.5 minutes in group 1 and 300 minutes in group 2 (p=0.008). In the early postoperative period, 10 people had postoperative complications. The median follow-up period was 68.17 ± 9.17 (95 % CI 17.00; 112.50) months in group 1 and 79.60 ± 12.17 (95 % CI 47.50; 123.50) in group 2 (p=0.493). The median RFS in group 1 was 139.86 ± 11.02 (95 % CI 119.00; 154.50) months and 100.67 ± 10.22 (95 % CI 91.00; 121.00) months in group 2 (p=0.375), while the local RFS was 174.80 ± 12.22 (95 % ci 139.00; 194.50) and 126.00 ± 11.40 (95 % CI 109.20; 142.40) months in groups 1 and 2, respectively (p=0.352). The median PFS was 193.00 ± 11.22 (95 % ci 172.02; 209.50) months in group 1 and 121.13 ± 11.14 (95 % CI 111.00; 146.43) months in group 2 (p=0.266). The median OS was 149.70 ± 11.20 (95 % CI 123.12; 161.43) months in the group 1 and 56.50 ± 11.20 (95 % CI 33.20; 78.42) months in the group 2 (p=0.169). The 5-year CSS was 85.7 % in group 1 and 40 % in group 2 (p=0.096). The 10-year CSS rate was 81 % and 4 % in groups 1 and 2, respectively (p=0.109). Conclusion. Surgical intervention is effective treatment for local recurrence, providing good oncological outcomes; however, size and proximity to neighboring organs can significantly impact the risk of perioperative complications.
- 19 March 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (1)
Surgical treatment of local renal cell carcinoma recurrence. Surgical aspects and oncological results
Introduction. Treatment of local RCC recurrence is a serious surgical and therapeutic problem. There is no single standard strategy for the treatment of locally recurrent RCC. Objective: to evaluate the short- and long-term results of surgical treatment of patients with local RCC recurrence. Material and methods. Among all participants (n=53), 48 patients had isolated local RCC recurrence (group 1), and 5 had synchronous metastases (group 2). All patients had one or more local foci of RCC and underwent radical removal of all foci from may 2007 to January 2024. In distant metastases, metastasectomy was performed. Results. Laparotomy was the preferred access (75.4 %). The average duration of surgery was 167.5 minutes in group 1 and 300 minutes in group 2 (p=0.008). In the early postoperative period, 10 people had postoperative complications. The median follow-up period was 68.17 ± 9.17 (95 % CI 17.00; 112.50) months in group 1 and 79.60 ± 12.17 (95 % CI 47.50; 123.50) in group 2 (p=0.493). The median RFS in group 1 was 139.86 ± 11.02 (95 % CI 119.00; 154.50) months and 100.67 ± 10.22 (95 % CI 91.00; 121.00) months in group 2 (p=0.375), while the local RFS was 174.80 ± 12.22 (95 % ci 139.00; 194.50) and 126.00 ± 11.40 (95 % CI 109.20; 142.40) months in groups 1 and 2, respectively (p=0.352). The median PFS was 193.00 ± 11.22 (95 % ci 172.02; 209.50) months in group 1 and 121.13 ± 11.14 (95 % CI 111.00; 146.43) months in group 2 (p=0.266). The median OS was 149.70 ± 11.20 (95 % CI 123.12; 161.43) months in the group 1 and 56.50 ± 11.20 (95 % CI 33.20; 78.42) months in the group 2 (p=0.169). The 5-year CSS was 85.7 % in group 1 and 40 % in group 2 (p=0.096). The 10-year CSS rate was 81 % and 4 % in groups 1 and 2, respectively (p=0.109). Conclusion. Surgical intervention is effective treatment for local recurrence, providing good oncological outcomes; however, size and proximity to neighboring organs can significantly impact the risk of perioperative complications.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 9-17
Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
Background: Immunotherapy-based regimens, such as nivolumab plus ipilimumab (Nivo-Ipi) and avelumab plus axitinib (Ave-Axi), are standard first-line treatments for metastatic clear-cell renal cell carcinoma (mRCC) with intermediate or poor IMDC risk. Comparative real-world evidence for these regimens remains limited.Methods: This retrospective cohort study included 102 patients with mRCC treated with Nivo-Ipi (n = 51) or AveAxi (n = 51) from 2018 to 2023. Propensity score matching was used to balance baseline characteristics, including IMDC risk and comorbidities. Primary endpoints were the rate of treatment-related adverse events (TRAEs) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and overall survival (OS).Results: Patient characteristics were balanced across cohorts, with a median age of 63.4 years, 76 % male, and 61 % having chronic cardiovascular diseases. The rate of any grade TRAEs was similar between Nivo-Ipi and Ave-Axi (62.7 % vs. 68.6 %, respectively), as was the rate of grade ≥ 3 TRAEs (11.7 % vs. 17.6 %). Patients treated with Ave-Axi had a significantly extended PFS (15.0 vs 9.7 months; p 0,05). The median OS was not reached.Conclusions: Nivo-Ipi and Ave-Axi are effective and well-tolerated first-line therapies for mRCC in real-world settings. Ave-Axi was associated with a significantly longer PFS and a numerically higher ORR compared to Nivo-Ipi.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 9-17
Open AccessAvelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
Background: Immunotherapy-based regimens, such as nivolumab plus ipilimumab (Nivo-Ipi) and avelumab plus axitinib (Ave-Axi), are standard first-line treatments for metastatic clear-cell renal cell carcinoma (mRCC) with intermediate or poor IMDC risk. Comparative real-world evidence for these regimens remains limited.Methods: This retrospective cohort study included 102 patients with mRCC treated with Nivo-Ipi (n = 51) or AveAxi (n = 51) from 2018 to 2023. Propensity score matching was used to balance baseline characteristics, including IMDC risk and comorbidities. Primary endpoints were the rate of treatment-related adverse events (TRAEs) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and overall survival (OS).Results: Patient characteristics were balanced across cohorts, with a median age of 63.4 years, 76 % male, and 61 % having chronic cardiovascular diseases. The rate of any grade TRAEs was similar between Nivo-Ipi and Ave-Axi (62.7 % vs. 68.6 %, respectively), as was the rate of grade ≥ 3 TRAEs (11.7 % vs. 17.6 %). Patients treated with Ave-Axi had a significantly extended PFS (15.0 vs 9.7 months; p 0,05). The median OS was not reached.Conclusions: Nivo-Ipi and Ave-Axi are effective and well-tolerated first-line therapies for mRCC in real-world settings. Ave-Axi was associated with a significantly longer PFS and a numerically higher ORR compared to Nivo-Ipi.
- Open Access
- 27 December 2024
- Published by MDPI AG in Current Oncology
- Vol. 32 (1) , 11
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.
- 27 December 2024
- Published by MDPI AG in Current Oncology
- Vol. 32 (1) , 11
Open AccessReal-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.
- Open Access
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 75-89
New capabilities of 2nd and subsequent therapy lines in metastatic urothelial cancer
According to the World Health Organization data, in 2022 bladder cancer (BC) was the 9th (614,298) most common cancer. In Russia, most patients (58.8 %) were diagnosed with non-muscle invasive BC (stage I) but the percentage of muscle invasive cancer (stages II–III) and metastatic BC (mBC) remains high: 32.1 and 8.3 % cases, respectively. Mortality in patients with BC in the first year since diagnosis remains high: 12.28 %. Decrease in BC mortality in the last 10 years in Russia by 22.84 % is probably due to development of new more effective drugs for mBC treatment which are the subject of this literature review.Currently, the 2nd line standards of treatment of patients with mBC changed due to appearance in the guidelines of the majority of the world oncological societies of new drugs classified as conjugated and targeted drugs. In patients with progression during platinum-based chemotherapy and/or immune checkpoint inhibitors, therapy with conjugate enfortumab vedotin (EV) is possible.Enfortumab vedotin is the first of its class drug, a conjugate of a monoclonal antibody against the nectin-4 protein which is highly expressed by urothelial carcinoma and a cytotoxic chemotherapy drug monomethyl auristatin E (ММАЕ) affecting microtubules. EV was approved by the US Food and Drug Administration (FDA) in December of 2019 based on phase II trial EV-201 as part of the expedited review program due to high rate of objective responses in patients with inoperable locally advanced and mBC who previously received platinum-based chemotherapy and immune checkpoint inhibitors. In Russia, the drug was approved in 2023.Median overall survival in all phase I–III EV trials were around 1 year and varied between 11.7 and 12.91 months, progression-free survival was a little below 6 months and varied between 5.5 and 5.8 months. In the UNITE trial based on routine practice data, median progression-free survival and overall survival since the start of EV therapy were a little higher than in the randomized trails: 6.8 and 14.4 months, respectively. Objective response rate in all clinical trials was above 40 %; in particular, in phase I trial EV-101 it was 43 %, in phase II trial EV-201 – 44 %, in phase III trial EV-301 – 41 %, and in UNITE – 52 %, while complete response rates were 5; 12; 6.9 and 7 %, respectively. In phase III clinical trial EV-301, EV therapy decreased the risk of death by 30 % compared to standard treatment (ST) and significantly increased overall survival from 8.94 months in the ST group to 12.91 months in the EV group. The risk of progression and death decreased by 37 % in the EV group, and median progression-free survival increased from 3.71 months in the ST group to 5.5 months in the EV group (p 0.00001). Additionally, objective response rate was more than 2-fold higher for EV compared to ST: 41.32 % versus 18.58 %. Approximately 30 % of patients in the EV group are alive at year 2 of the study compared to 20 % in the ST group. Safety profile also demonstrates similar results to the intermediate and primary analyses. The rates of treatment-associated adverse events of grade III or higher in the EV group in both intermediate and primary analyses of the EV-301 trial (51.4 and 52.4 %, respectively) were similar to the rates in the ST group (49.8 % and 50.5 %, respectively). The most common adverse events in the EV therapy group were rash, hyperglycemia, and peripheral neuropathy. At the same time, quality of life in the EV therapy group was higher compared to the standard therapy which confirms safety and effectiveness of EV in patients with urothelial carcinoma.
- 1 December 2024
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 20 (4) , 75-89
Open AccessNew capabilities of 2nd and subsequent therapy lines in metastatic urothelial cancer
According to the World Health Organization data, in 2022 bladder cancer (BC) was the 9th (614,298) most common cancer. In Russia, most patients (58.8 %) were diagnosed with non-muscle invasive BC (stage I) but the percentage of muscle invasive cancer (stages II–III) and metastatic BC (mBC) remains high: 32.1 and 8.3 % cases, respectively. Mortality in patients with BC in the first year since diagnosis remains high: 12.28 %. Decrease in BC mortality in the last 10 years in Russia by 22.84 % is probably due to development of new more effective drugs for mBC treatment which are the subject of this literature review.Currently, the 2nd line standards of treatment of patients with mBC changed due to appearance in the guidelines of the majority of the world oncological societies of new drugs classified as conjugated and targeted drugs. In patients with progression during platinum-based chemotherapy and/or immune checkpoint inhibitors, therapy with conjugate enfortumab vedotin (EV) is possible.Enfortumab vedotin is the first of its class drug, a conjugate of a monoclonal antibody against the nectin-4 protein which is highly expressed by urothelial carcinoma and a cytotoxic chemotherapy drug monomethyl auristatin E (ММАЕ) affecting microtubules. EV was approved by the US Food and Drug Administration (FDA) in December of 2019 based on phase II trial EV-201 as part of the expedited review program due to high rate of objective responses in patients with inoperable locally advanced and mBC who previously received platinum-based chemotherapy and immune checkpoint inhibitors. In Russia, the drug was approved in 2023.Median overall survival in all phase I–III EV trials were around 1 year and varied between 11.7 and 12.91 months, progression-free survival was a little below 6 months and varied between 5.5 and 5.8 months. In the UNITE trial based on routine practice data, median progression-free survival and overall survival since the start of EV therapy were a little higher than in the randomized trails: 6.8 and 14.4 months, respectively. Objective response rate in all clinical trials was above 40 %; in particular, in phase I trial EV-101 it was 43 %, in phase II trial EV-201 – 44 %, in phase III trial EV-301 – 41 %, and in UNITE – 52 %, while complete response rates were 5; 12; 6.9 and 7 %, respectively. In phase III clinical trial EV-301, EV therapy decreased the risk of death by 30 % compared to standard treatment (ST) and significantly increased overall survival from 8.94 months in the ST group to 12.91 months in the EV group. The risk of progression and death decreased by 37 % in the EV group, and median progression-free survival increased from 3.71 months in the ST group to 5.5 months in the EV group (p 0.00001). Additionally, objective response rate was more than 2-fold higher for EV compared to ST: 41.32 % versus 18.58 %. Approximately 30 % of patients in the EV group are alive at year 2 of the study compared to 20 % in the ST group. Safety profile also demonstrates similar results to the intermediate and primary analyses. The rates of treatment-associated adverse events of grade III or higher in the EV group in both intermediate and primary analyses of the EV-301 trial (51.4 and 52.4 %, respectively) were similar to the rates in the ST group (49.8 % and 50.5 %, respectively). The most common adverse events in the EV therapy group were rash, hyperglycemia, and peripheral neuropathy. At the same time, quality of life in the EV therapy group was higher compared to the standard therapy which confirms safety and effectiveness of EV in patients with urothelial carcinoma.